Business Wire 19-May-2017 4:05 PM
EMERYVILLE, Calif.--(BUSINESS WIRE)-- NovaBayPharmaceuticals, Inc. (NYSE MKT: NBY) today announced receipt of a letter from NYSE MKT LLC (NYSE MKT or the Exchange) on May 16, 2017, stating that it is not in compliance with the continued listing standards (requiring stockholders equity of $6.0 million or more if it has reported losses from continuing operations and/or net losses in its five most recent fiscal years) as set forth in Section 1003(a)(iii) of the NYSE MKT Company Guide (Company Guide).
In order to maintain its listing, NovaBay Pharmaceuticals must submit a plan of compliance by June 15, 2017, addressing how it intends to regain compliance with Section 1003(a)(iii) of the Company Guide.
The Company intends to submit a plan to regain compliance with NYSE MKT listing standards. If the plan is not accepted, delisting proceedings will commence. If the plan is accepted, the Companys common stock will continue to be listed on the NYSE MKT during the plan period. However, if the Company does not regain compliance with those standards or does not make progress consistent with the plan, the NYSE MKT staff may commence delisting proceedings.
About NovaBay Pharmaceuticals, Inc.: Going Beyond Antibiotics
NovaBay Pharmaceuticals, Inc. is a biopharmaceutical company focusing on commercializing and developing its non-antibiotic anti-infective products to address the unmet therapeutic needs of the global, topical anti-infective market with its two distinct product categories: the NEUTROX family of products and the AGANOCIDE compounds. The Neutrox family of products includes AVENOVA for the eye care market, NEUTROPHASE for wound care market, and CELLERX for the aesthetic dermatology market. The Aganocide compounds, still under development, have target applications in the dermatology and urology markets.
Stay informed on NovaBays progress: Download our Mobile InvestorApp from the Apple Store or Google Play Like us on Facebook Follow us on Twitter Connect with NovaBay on LinkedIn Join us on Google+ Visit NovaBays Website
NovaBay Contacts For NovaBay Avenova purchasing information, please contact:800-890-0329www.Avenova.com
View source version on businesswire.com: http://www.businesswire.com/news/home/20170519005093/en/
Source: NovaBay Pharmaceuticals, Inc.
Limited Time Offer:
Claim your free copy of income expert Bryan Perry's new report:
My Top Monthly Dividend Payer (8% Dividend Yield)
You'll also receive Bryan Perry's weekly e-letter, Dividend Investing Weekly, at no cost, along with other associated financial content and special offers.